Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities - a podcast by American Society of Clinical Oncology (ASCO)

Patients with epidermal growth factor receptor (EGFR) gene mutations should receive EGFR tyrosine kinase inhibitors as 1st line therapy because they produce higher response rates, long progression free survival, reduced toxicity, improved symptom control and convenience of oral administration compared to chemotherapy doublets.

Further episodes of Journal of Clinical Oncology (JCO) Podcast

Further podcasts by American Society of Clinical Oncology (ASCO)

Website of American Society of Clinical Oncology (ASCO)